-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prestige BioPharma announced that the U.SFoodand Drug Administration(
FDA) has awarded orphan drug drugs (ODD) for its-up factor (PAUF) monoclonal antibody PBP1510 for the treatment of pancreatic cancerPancreatic cancer is a highly invasive malignant tumor with high morbidity and mortality, with a five-year survival rate of only 9% in the United StatesCurrently, the only treatment option is limited to surgical excision combined with complementary chemotherapyHowever, only 10% to 15% of patients are available because most patients are in a late or metastatic stage at the time ofdiagnosis andand are unable to undergo surgerythe expression of pancreatic adenocarcinoma (PAUF) plays an important role in pancreatic cancer progression, there is currently no targeted molecular therapy for PAUFDrLisa SPark, CEO of Prestige BioPharma, said, "The FDA's orphan drug designation is critical to accelerating the development of PBP1510 and providing a better treatment strategy for pancreatic cancer"
FDA awarded THE OD, the drug for the treatment, diagnosis, or prevention affecting less than 200,000 people in the United States Prestige Biopharma has also applied to the European Medicines Agency for the european Union's designated orphan drug designation
